Company intelligence / Profile preview

Orio Therapeutics

Monthey, Valais, Switzerlandoriotx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Orio Therapeutics has developed a patented technology to engineer therapeutic proteins for improved local delivery. Their lead program—a cardioprotective drug for heart attack patients—is entering pre-clinical studies following a CHF 500,000 pre-seed funding round. The approach aims to reduce side effects and costs by enhancing the retention of drugs at the target site, thus improving outcomes in regenerative medicine applications such as myocardial infarction.

Therapeutic areas: Cardiovascular
Modalities: Protein-based therapeutics (engineered proteins with built-in delivery systems)
Industry: Biotech

Drug pipeline

1 asset

Not disclosed

Pre-clinical

Indications: Myocardial infarction

Beyond the preview

Go deeper on Orio Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orio Therapeutics.

Explore the full profile